Cargando…

Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States

Background/objectives: The COVID-19 pandemic impacted healthcare visit trends, propelling healthcare systems to reduce in-person visits and hospital admissions and increasingly rely on telemedicine; whether there are differences in these trends across racial groups is unknown. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neparidze, Natalia, Lau, Krystal W., Wang, Xiaoliang, Davidoff, Amy J., Huntington, Scott F., Jamy, Omer Hassan, Calip, Gregory, Shah, Harsh, Stephens, Deborah M., Miksad, Rebecca A., Parikh, Ravi, Takvorian, Samuel, Goyal, Gaurav, Seymour, Erlene K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	905.Outcomes Research-Lymphoid Malignancies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701527/ http://dx.doi.org/10.1182/blood-2021-153787

Ejemplares similares

Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States
por: Goyal, Gaurav, et al.
Publicado: (2021)

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
por: Neparidze, Natalia, et al.
Publicado: (2021)

The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021
por: Goyal, Gaurav, et al.
Publicado: (2023)

COVID-19 in Children, Adolescents and Young Adults with Hematological Malignancies
por: Parker, Rebecca S, et al.
Publicado: (2021)

COVID-19 Vaccine Response in Patients with Hematologic Malignancy: A Systematic Review and Meta-Analysis
por: Gong, Inna, et al.
Publicado: (2021)

Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020
por: Smart, Dave, et al.
Publicado: (2021)

Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology
por: Hicks, Lisa K., et al.
Publicado: (2021)

Acute and Post-Acute COVID-19 Severity and Mortality in Patients with Hematologic Malignancies: A Population-Based Registry Study
por: Martinez-Lopez, Joaquin, et al.
Publicado: (2021)

Association of Race, Ethnicity, Age and Socioeconomic Status with Access to Virtual Visits within the Brigham & Women's Hospital Division of Hematology during the COVID-19 Pandemic
por: Kwarteng-Siaw, Miriam, et al.
Publicado: (2021)

COVID-19 Among Patients with Hematological Malignancies: Experience from a Tertiary Center Showing Lower Than Expected Mortality and Establishing the Safety of in-Hospital Patient Care during the Pandemic
por: Aumann, Shlomzion, et al.
Publicado: (2021)

Utilizing HealthTree ® Cure Hub's Real-World Data to Assess Treatment Management of Patients with Multiple Myeloma during the COVID-19 Pandemic
por: Sweeney, Nathan W., et al.
Publicado: (2021)

A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy
por: Choi, Yun, et al.
Publicado: (2021)

Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021)

COVID-19 in Multiple Myeloma Patients: Frequencies and Risk Factors for Hospitalization, Ventilatory Support, Intensive Care Admission and Mortality -Cooperative Registry from Grupo Brasileiro De Mieloma Multiplo (GBRAM)
por: Garnica, Marcia, et al.
Publicado: (2021)

Blood Type Does Not Affect Morbidity or Mortality in COVID-19 Infections, As Assessed By a Clinical Severity Scoring System
por: Thomas, Katharine E, et al.
Publicado: (2021)

Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19
por: Cook, Michael Roderick, et al.
Publicado: (2020)

Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience
por: Galvez, Carlos, et al.
Publicado: (2020)

Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients
por: D'Aiello, Angelica, et al.
Publicado: (2020)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK
por: Cranmer, Holly, et al.
Publicado: (2020)

COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study
por: Ip, Andrew, et al.
Publicado: (2020)

IMMUNE THROMBOCYTOPENIA PURPURA ASSOCIATED WITH NOVEL CORONAVIRUS INFECTION
por: Camelo, R.M., et al.
Publicado: (2020)

Neutralizing monoclonal antibodies for early treatment of hospital‐acquired SARS‐CoV‐2 infection in hematologic patients
por: Bussini, Linda, et al.
Publicado: (2022)

Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK
por: Hillmen, Peter, et al.
Publicado: (2021)

Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020)

Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020)

Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)

Genetic aberrations of NLRC5 are associated with downregulated MHC‐I antigen presentation and impaired T‐cell immunity in follicular lymphoma
por: Gunawardana, Jay, et al.
Publicado: (2020)

Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect(®) CLL Registry
por: Sharman, Jeff P., et al.
Publicado: (2020)

Clinical features of anthracycline‐induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single‐center, retrospective observational study
por: Nakayama, Takafumi, et al.
Publicado: (2020)

Immune reconstitution in children following chemotherapy for acute leukemia
por: Williams, Anthony P., et al.
Publicado: (2020)

The contribution of human papilloma virus infection to cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia
por: Bhavsar‐Bhakta, Preeya, et al.
Publicado: (2021)

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma
por: Ribrag, Vincent, et al.
Publicado: (2022)

Phase II study of dose‐adjusted gemcitabine, dexamethasone, cisplatin, and rituximab in elderly relapsed diffuse large B‐cell lymphoma patients
por: Yamasaki, Satoshi, et al.
Publicado: (2020)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients
por: Singh, Namrata, et al.
Publicado: (2020)

First‐line treatment of stage IIB to stage IV classical Hodgkin lymphoma in Italy, Israel, and Spain: Patient characteristics, treatment patterns, and clinical outcomes
por: Avigdor, Abraham, et al.
Publicado: (2022)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

A prognostic model integrating PET‐derived metrics and image texture analyses with clinical risk factors from GOYA
por: Kostakoglu, Lale, et al.
Publicado: (2022)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_j9e9jsb2r0n9rh4vkg2b4of3bi